Trial Profile
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sepantronium bromide (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 19 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 16 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 16 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.